(BAYN) Bayer NA - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000BAY0017
BAYN: Medicines, Drugs, Seeds, Therapies, Supplements, Chemicals
Bayer Aktiengesellschaft is a global life science powerhouse, operating at the intersection of healthcare and agriculture. Its diversified business model is divided into three core segments: Pharmaceuticals, Consumer Health, and Crop Science.
The Pharmaceuticals division is the companys largest revenue generator, focusing on innovative treatments for critical areas such as cardiology, womens health, oncology, and ophthalmology. It also develops cutting-edge therapies in cell and gene therapy, positioning Bayer as a leader in next-generation medical treatments. Strategic collaborations with institutions like MD Anderson Cancer Center and Dewpoint Therapeutics underscore its commitment to advancing oncology and cardiovascular therapies.
The Consumer Health segment is a staple in everyday healthcare, offering a broad portfolio of over-the-counter medications, skincare products, and nutritional supplements. This division caters to widespread health needs, from pain management and digestive health to allergy relief, making it a reliable contributor to Bayers steady cash flow.
Crop Science is Bayers agricultural arm, providing farmers with high-tech solutions to enhance yields and sustainability. This includes seed technology, pest control, and digital farming tools. The segments focus on innovation addresses global food security challenges, aligning with the growing demand for efficient agricultural practices.
Bayers extensive distribution network ensures its products reach a wide audience, from pharmacies and supermarkets to hospitals and farmers. Its collaborations with academic institutions and biotech firms highlight a commitment to R&D, crucial for long-term growth in competitive markets.
Founded in 1863, Bayers legacy is built on scientific excellence and innovation. Headquartered in Leverkusen, Germany, the company continues to be a key player in global healthcare and agriculture. For more information, visit https://www.bayer.com.
Market Cap: 21,259.66M EUR | P/E: 0.00 | Forward P/E: 1.65 | P/B: 0.70 | P/S: 0.45
Additional Sources for BAYN Stock
BAYN Stock Overview
| Market Cap in USD | 25,545m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
BAYN Stock Ratings
| Growth 5y | -64.8% |
| Fundamental | -14.4% |
| Dividend | 0.62% |
| Rel. Strength | -24.4 |
| Analysts | - |
| Fair Price Momentum | 19.69 EUR |
| Fair Price DCF | 95.28 EUR |
BAYN Dividends
| Dividend Yield 12m | 0.93% |
| Yield on Cost 5y | 0.46% |
| Annual Growth 5y | -47.66% |
| Payout Consistency | 85.9% |
BAYN Growth Ratios
| Growth Correlation 3m | 81.8% |
| Growth Correlation 12m | -70.2% |
| Growth Correlation 5y | -53.9% |
| CAGR 5y | -14.51% |
| CAGR/Max DD 5y | -0.20 |
| Sharpe Ratio 12m | -0.38 |
| Alpha | -31.81 |
| Beta | 1.045 |
| Volatility | 34.05% |
| Current Volume | 4269.2k |
| Average Volume 20d | 4196.2k |
As of April 03, 2025, the stock is trading at EUR 21.43 with a total of 4,269,244 shares traded.
Over the past week, the price has changed by -5.97%, over one month by -10.73%, over three months by +10.51% and over the past year by -23.16%.
Neither. Based on ValueRay Fundamental Analyses, Bayer NA is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BAYN as of April 2025 is 19.69. This means that BAYN is currently overvalued and has a potential downside of -8.12%.
Bayer NA has no consensus analysts rating.
According to ValueRays Forecast Model, BAYN Bayer NA will be worth about 21.3 in April 2026. The stock is currently trading at 21.43. This means that the stock has a potential downside of -0.75%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 28.1 | 30.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21.3 | -0.7% |